IGC Announces Phytocannabinoid Focused Pharmaceutical Unit

IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in its effort to gain a leading position in the emerging legal cannabis industry.  Our strategy is to develop a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of therapeutic indications including pain, epilepsy, and other niche severe terminal diagnosis, which are life altering or life threatening.   Most recently, the company applied for a provisional patent based on a novel therapy that uses cannabinoid extracts for the treatment of seizures in dogs and cats. The therapy, which is expected to also have applications in humans, is administered using a variety of delivery technologies. We expect to establish metabolic profiling and apply to the FDA for trials.To facilitate the development of the product portfolio, IGC is entering into partnerships with a range of organizations that can provide cost effective solutions for metabolic profiling, clinical trials, and regulatory approvals that in most cases will be necessary to eventually commercialize our products."The Company is also continuing to assemble an international network of doctors, veterinarians, and researchers with extensive expertise in various indications, medicines containing controlled substances, plant-based products, extraction technologies, and drug delivery technologies.  In addition, we have assembled experts in patent law, clinical trials, and regulatory procedures," said Ram Mukunda, IGC's CEO.Mukunda added,